{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:21Z","timestamp":1792511601892,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.autrev.2020.102658","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T11:30:04Z","timestamp":1600083004000},"page":"102658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases"],"prefix":"10.1016","volume":"19","author":[{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levente","family":"Bodoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Andr\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e1r\u00f3czy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Antal-Szalm\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Szodoray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"\u00c1rkosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dank\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Tam\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102658_bb0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.autrev.2006.03.007","article-title":"Malignancies and soluble tumor antigens in rheumatic diseases","volume":"6","author":"Szekanecz","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000314634","article-title":"Malignancies in autoimmune rheumatic diseases - a mini-review","volume":"57","author":"Szekanecz","year":"2011","journal-title":"Gerontology"},{"key":"10.1016\/j.autrev.2020.102658_bb0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2020.102658_bb0025","first-page":"839","article-title":"Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases","volume":"32","author":"Cutolo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0030","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.autrev.2012.02.021","article-title":"Malignancies associated with systemic sclerosis","volume":"11","author":"Szekanecz","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-008-0925-x","article-title":"Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis","volume":"27","author":"Szekanecz","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1422.008","article-title":"Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center","volume":"1108","author":"Tarr","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2020.102658_bb0045","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/957151","article-title":"Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases","volume":"2012","author":"Nakken","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","article-title":"Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study","volume":"22","author":"Varoczy","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2020.102658_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1573395511309010003","article-title":"Possible mechanisms of lymphoma development in Sjogren\u2019s syndrome","volume":"9","author":"Dong","year":"2013","journal-title":"Curr Immunol Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1568-9972(03)00102-2","article-title":"Lymphoproliferative disorders in Sjogren\u2019s syndrome","volume":"3","author":"Masaki","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.autrev.2009.12.005","article-title":"Polymyositis, dermatomyositis and malignancy: a further intriguing link","volume":"9","author":"Zampieri","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0070","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.berh.2008.09.007","article-title":"Epstein-Barr virus in autoimmune diseases","volume":"22","author":"Toussirot","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0075","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.38201","article-title":"Structural lung changes and local anti-citrulline immunity are early features of anti citrullinated-proteins antibodies positive rheumatoid arthritis","volume":"66","author":"Reynisdottir","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0085","first-page":"391","article-title":"Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis","volume":"55","author":"Catrina","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0090","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s10067-014-2789-6","article-title":"Occurrence of pulmonary rheumatoid nodules following biological therapies","volume":"34","author":"Kovacs","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0095","first-page":"1","article-title":"Advances at the interface of cancer and systemic sclerosis","volume":"2020","author":"Mecoli","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2020.102658_bb0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2006.066340","article-title":"Survival and causes of death in 366 Hungarian patients with systemic sclerosis","volume":"67","author":"Czirjak","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian rheumatologic Center and a population-based Cancer registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0115","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s12253-019-00756-4","article-title":"Retrospective analysis of Cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort","volume":"26","author":"Andras","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.autrev.2020.102658_bb0120","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andras","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2020.102658_bb0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2009.07.004","article-title":"Malignancies in systemic lupus erythematosus","volume":"9","author":"Kiss","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2009.07.002","article-title":"Secondary tumours in Sjogren\u2019s syndrome","volume":"9","author":"Kovacs","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-3083.2009.02237.x","article-title":"Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy","volume":"69","author":"Illes","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sjogren\u2019s syndrome: predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0150","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","article-title":"Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study","volume":"62","author":"Simard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0155","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","article-title":"Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden","volume":"66","author":"Hellgren","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0160","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2005.047514","article-title":"Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"F.t.D.S.G. Artis study group, Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0170","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/rheumatology\/ken060","article-title":"Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224","volume":"47","author":"Wick","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0175","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3389\/fimmu.2018.03136","article-title":"Primary immunodeficiency and cancer predisposition revisited: embedding two closely related concepts into an integrative conceptual framework","volume":"9","author":"Haas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fped.2019.00232","article-title":"Primary Immunodeficiencies and oncological risk: the experience of the Children\u2019s Hospital of Brescia","volume":"7","author":"Maffeis","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.autrev.2020.102658_bb0185","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1940-6207.CAPR-16-0209","article-title":"Targeting inflammation in Cancer prevention and therapy","volume":"9","author":"Todoric","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.autrev.2020.102658_bb0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1588084","article-title":"Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival","volume":"8","author":"Watad","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2020.102658_bb0200","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0205","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102658_bb0210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102658_bb0225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2020.102658_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","article-title":"The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren\u2019s syndrome","volume":"62","author":"Szodoray","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrc2857","article-title":"Helicobacter pylori: gastric cancer and beyond","volume":"10","author":"Polk","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2020.102658_bb0240","doi-asserted-by":"crossref","first-page":"e6026","DOI":"10.1371\/journal.pone.0006026","article-title":"Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility","volume":"4","author":"Uronis","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102658_bb0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0250","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1196\/annals.1422.037","article-title":"Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?","volume":"1108","author":"Szekanecz","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2020.102658_bb0255","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaut.2008.08.008","article-title":"Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices","volume":"31","author":"Szekanecz","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2020.102658_bb0260","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/clin.1995.1113","article-title":"Increased synovial expression of the adhesion molecules CD66a, CD66b, and CD31 in rheumatoid and osteoarthritis","volume":"76","author":"Szekanecz","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.autrev.2020.102658_bb0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1346-8138.1995.tb03336.x","article-title":"Elevated serum CA125 in progressive systemic sclerosis with pleural effusion","volume":"22","author":"Kimura","year":"1995","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/pgmj.74.875.543","article-title":"Increased serum CA 19-9 antibodies in Sjogren\u2019s syndrome","volume":"74","author":"Safadi","year":"1998","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.autrev.2020.102658_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0280","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0285","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"C. British Society for Rheumatology biologics register control centre, risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0295","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology biologics register for rheumatoid arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0300","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Rheumatic therapy in Sweden study, malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, Tocilizumab, Abatacept, or rituximab in clinical practice: a Nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0305","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0310","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","article-title":"Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses","volume":"23","author":"Behrens","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0320","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","article-title":"Leflunomide: a promising drug with good antitumor potential","volume":"496","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2020.102658_bb0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jss.2013.05.089","article-title":"Leflunomide suppresses growth in human medullary thyroid cancer cells","volume":"185","author":"Alhefdhi","year":"2013","journal-title":"J Surg Res"},{"key":"10.1016\/j.autrev.2020.102658_bb0330","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2020.102658_bb0335","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.rdc.2012.09.006","article-title":"Malignancy risks with biologic therapies","volume":"38","author":"Cush","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102658_bb0340","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.autrev.2010.07.011","article-title":"Biologics - beyond the joints","volume":"9","author":"Szekanecz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0345","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102658_bb0350","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2020.102658_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2020.102658_bb0360","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rdc.2016.09.008","article-title":"Malignancy and Janus kinase inhibition","volume":"43","author":"Sivaraman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102658_bb0365","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0370","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0375","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40744-018-0128-0","article-title":"Safety and efficacy of Baricitinib in patients receiving conventional synthetic disease-modifying antirheumatic drugs or corticosteroids","volume":"5","author":"van Vollenhoven","year":"2018","journal-title":"Rheumatol Therapy"},{"key":"10.1016\/j.autrev.2020.102658_bb0380","first-page":"694","article-title":"The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib","volume":"37","author":"Choy","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0385","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102658_bb0390","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102658_bb0395","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0400","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and Cancer recurrence in Swedish patients with rheumatoid arthritis: a Nationwide population-based cohort study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0405","first-page":"1224","article-title":"Physiotherapy of cancer patients","volume":"157","author":"Gomez","year":"2016","journal-title":"Hung Med J"},{"key":"10.1016\/j.autrev.2020.102658_bb0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ctrv.2016.11.010","article-title":"Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs","volume":"52","author":"Buffart","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0415","first-page":"24","article-title":"Physical therapy methods for treatment and rehabilitation of oncologic patients (review of literature)","author":"Kotenko","year":"2016","journal-title":"Med Tr Prom Ekol"},{"key":"10.1016\/j.autrev.2020.102658_bb0420","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/tbj.13744","article-title":"Hydrotherapy following breast cancer surgery phase II trial on hydrotherapy in women following breast cancer surgery","volume":"26","author":"Siqueira","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.autrev.2020.102658_bb0425","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","article-title":"Paraneoplastic syndromes in rheumatology","volume":"10","author":"Manger","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0430","first-page":"4","article-title":"Clinical importance of paraneoplasias in rheumatology","volume":"5","author":"Andr\u00e1s","year":"2006","journal-title":"Hung Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102422","article-title":"Aetiology and pathogenesis of paraneoplastic autoimmune disorders","volume":"19","author":"Geng","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0440","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.autrev.2008.02.001","article-title":"Rheumatic disorders as paraneoplastic syndromes","volume":"7","author":"Racanelli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0445","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.autrev.2010.10.006","article-title":"Solid cancer, antiphospholipid antibodies, and venous thromboembolism","volume":"10","author":"Font","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0450","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.autrev.2009.04.001","article-title":"Antiphospholipid antibodies and malignancies","volume":"9","author":"Tincani","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0455","first-page":"2917","article-title":"Catastrophic antiphospholipid antibody syndrome in a cancer patient","volume":"140","author":"Soltesz","year":"1999","journal-title":"Orv Hetil"},{"key":"10.1016\/j.autrev.2020.102658_bb0460","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1163\/156855900300109549","article-title":"Catastrophic antiphospholipid syndrome in cancer","volume":"30","author":"Soltesz","year":"2000","journal-title":"Haematologia (Budap)"},{"key":"10.1016\/j.autrev.2020.102658_bb0465","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2362.1993.tb02032.x","article-title":"The aetiology of clubbing and hypertrophic osteoarthropathy","volume":"23","author":"Dickinson","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102658_bb0470","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","article-title":"Molecular mechanisms of bone metastasis and associated muscle weakness","volume":"20","author":"Waning","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2020.102658_bb0475","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.v17i1.474","article-title":"Management of aromatase inhibitor-induced arthralgia","volume":"17","author":"Younus","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0480","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in hematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.autrev.2020.102658_bb0485","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud's phenomenon: beyond beta-adrenoceptor blockers","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2020.102658_bb0490","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2013.36","article-title":"Management of cancer treatment-induced bone loss","volume":"9","author":"Coleman","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0495","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0500","first-page":"23","article-title":"Immunological and immunooncological role of PD-1 and PD-L1","volume":"9","author":"Szekanecz","year":"2017","journal-title":"Immunol Quarterly (Budapest)"},{"key":"10.1016\/j.autrev.2020.102658_bb0505","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tips.2015.06.005","article-title":"New immunotherapies targeting the PD-1 pathway","volume":"36","author":"Chinai","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2020.102658_bb0510","first-page":"887","article-title":"[autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment], hung","volume":"160","author":"Szekanecz","year":"2019","journal-title":"Medizinhist J"},{"key":"10.1016\/j.autrev.2020.102658_bb0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0525","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0530","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102658_bb0535","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0540","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102658_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102658_bb0550","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0555","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Tocut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0560","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.autrev.2019.06.005","article-title":"Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer","volume":"18","author":"Sebastiani","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0565","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102658_bb0570","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102658_bb0575","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10753-015-0132-2","article-title":"Analysis of programmed Death-1 in patients with psoriatic arthritis","volume":"38","author":"Peled","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.autrev.2020.102658_bb0580","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0585","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102658_bb0590","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0595","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Cancer, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0600","doi-asserted-by":"crossref","first-page":"vii49","DOI":"10.1093\/rheumatology\/kez360","article-title":"Management of rheumatic complications of ICI therapy: a rheumatology viewpoint","volume":"58","author":"Leipe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0605","doi-asserted-by":"crossref","first-page":"vii29","DOI":"10.1093\/rheumatology\/kez536","article-title":"Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective","volume":"58","author":"Steven","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102658_bb0610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2020.102658_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102456","article-title":"Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102658_bb0620","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-018-0937-6","article-title":"Nobel committee honors tumor immunologists","volume":"37","author":"Rotte","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.autrev.2020.102658_bb0625","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Study, adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0630","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0635","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0640","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0959-8049(02)00478-1","article-title":"Osteosarcoma over the age of forty","volume":"39","author":"Grimer","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2020.102658_bb0645","first-page":"237","article-title":"New aspects in the treatment of bone sarcomas","volume":"50","author":"Szendroi","year":"1994","journal-title":"Acta Med Hung"},{"key":"10.1016\/j.autrev.2020.102658_bb0650","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/pbc.26087","article-title":"A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma","volume":"63","author":"Anderson","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl. 7","key":"10.1016\/j.autrev.2020.102658_bb0655","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2020.102658_bb0660","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1096-9098(200002)73:2<87::AID-JSO6>3.0.CO;2-P","article-title":"Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience","volume":"73","author":"Szendroi","year":"2000","journal-title":"J Surg Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:11Z","timestamp":1761600011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":132,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1568997220302330"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102658","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102658"}}